Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe NowIndianapolis-based Eli Lilly and Co. reported third-quarter results Thursday that easily topped Wall Street expectations, with revenue of $17.6 billion—up 54% from a year ago, driven by huge growth in sales of weight-loss and diabetes medications Zepbound and Mounjaro.
For the quarter, Lilly reported adjusted earnings of $7.02 a share, compared with the $6.02 consensus estimate, according to analysts at Zachs Investment Research.
Shares of Lilly rose almost 5% in premarket trading, to $853.50 a share, as the company also raised its guidance for the year, with the company now expecting revenue in the range of $63 billion to $63.5 billion, up from the $61.7 billion expected by Zachs estimates.
Shares were up 3.3% at midday, to $840 each.
Lily reported profit of $5.58 billion for the third quarter, up from $970.3 million in the same period a year earlier.
Lilly is using the growth in capital to make significant billion-dollar investments in U.S. manufacturing, with recent announcements for new sites in Virginia and Texas and an expansion in Puerto Rico. Much of that is to support its highly anticipated GLP-1 oral weight-loss medication in late-stage clinical trials, orforglipron.
“Lilly delivered another strong quarter, with 54% revenue growth year-over-year driven by continued demand for our incretin portfolio,” Lilly CEO David Ricks said in written remarks. “We advanced orforglipron through four additional Phase 3 trials, enabling global obesity submissions by year-end.
“We continue to increase manufacturing capacity, announcing new facilities in Virginia and Texas and an expansion of our site in Puerto Rico.”
For now, though, Zepbound and Mounjaro remain the engines of growth.
Sales of Mounjaro totaled $6.52 billion for the quarter, up 109% from the same quarter a year ago. Zepound revenue was $3.59 billion, up 185%.
Together the two GLP-1 drugs accounted for roughly 57% of revenue.
Lilly’s U.S. business was key. Revenue in the United States was $11.30 billion for the quarter, up 45% from a year ago. Lilly said that gain was driven by a 60% increase in volume, partially offset by a 15% decrease due to lower realized prices.
In its earnings news release, Lilly noted that its increased revenue forecast was “primarily driven by strong underlying business performance across the portfolio.”
Please enable JavaScript to view this content.
Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our comment policy that will govern how comments are moderated.